Fig. 2: Modulation of pERK1/2T202/Y204 and pMEK1/2S217/221 expression levels in paired skin biopsies from patients in cohorts 1-4. | BJC Reports

Fig. 2: Modulation of pERK1/2T202/Y204 and pMEK1/2S217/221 expression levels in paired skin biopsies from patients in cohorts 1-4.

From: A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Fig. 2

a Cohort 1 and 2: PD-0325901 2 mg B.D. b Cohort 3: PD-0325901 4 mg B.D. c Cohort 4: PD-0325901 8 mg B.D. d Densitometry was performed on the WB images using ImageJ software. SC = screening. C1D15: Skin biopsy obtained between 3 and 6 h following morning dose of PD-0325901.

Back to article page